Association between a constipation scoring system adapted for use in children and the dysfunctional voiding symptom score in children and adolescents with lower urinary tract symptoms

Objective: Double-J stent is a common tool used in urological procedures that is inserted for 2–6 weeks, but it may induce abdominal and flank pain, incontinence and irritative urinary symptoms. Alleviation of such symptoms would be useful to improve the patients’ quality of life. Accordingly, in this study, the efficacy of cystone versus tamsulosin in the treatment of double-J stent-related lower urinary tract symptoms was determined. Materials and methods: In this randomised clinical trial, 128 patients who required double-J stent insertion after transureteral lithotripsy during 2018–2019 were enrolled. They were randomly assigned to receive either cystone, tamsulosin, both, or placebo. The international prostate symptom score and visual analogue score data were recorded at baseline, after 2 and 4 weeks across the groups. Results: The international prostate symptom score and visual analogue score factors were statistically different across the case groups receiving cystone, tamsulosin and both drugs versus placebo ( P=0.001). Two weeks after drug administration, the visual analogue score and international prostate symptom score were not statistically different in the tamsulosin, cystone and dual therapy groups; however, after 4 weeks the cystone group had the lowest symptoms. Conclusion: Both tamsulosin and cystone are efficient drugs which would relieve stent-related lower urinary tract symptoms. The administration of cystone with or without tamsulosin for 4 weeks may have the best result in reducing the visual analogue score and international prostate symptom score. Level of evidence: Level I, 1b, therapeutic study, randomised controlled trial

Download Full-text

How international is the International Prostate Symptom Score? A literature review of validated translations of the IPSS , the most widely used self‐administered patient questionnaire for male lower urinary tract symptoms

LUTS Lower Urinary Tract Symptoms ◽

10.1111/luts.12415 ◽

2021 ◽

Author(s):

Mark W. Yao ◽

James S. A. Green

Keyword(s):

Urinary Tract ◽

Literature Review ◽

Symptom Score ◽

Lower Urinary Tract Symptoms ◽

International Prostate Symptom Score ◽

Lower Urinary Tract ◽

Patient Questionnaire ◽

Urinary Tract Symptoms ◽

Lower Urinary

Download Full-text

Surveying the Prevalence of Lower Urinary Tract Symptoms Based on Individual and Clinical Parameters in Patients with Multiple Sclerosis

10.21203/rs.2.10499/v1 ◽

2019 ◽

Author(s):

Fatemeh Nazari ◽

Vahid Shaygannejad ◽

Mehrdad Mohammadi Sichani ◽

Marjan Mansourian Gharaagozlou ◽

Valiollah Hajhashemi

Keyword(s):

Multiple Sclerosis ◽

Urinary Tract ◽

Symptom Score ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Statistical Tests ◽

Men And Women ◽

Urinary Tract Symptoms ◽

Significant Difference ◽

Lower Urinary

Abstract Background Most patients with multiple sclerosis (MS) suffer from bladder dysfunction during the course of the disease. This study was conducted to examine the prevalence of these complications among patients with MS. Methods This cross-sectional study was performed on 603 patients with MS who referred to the neurology clinics of Kashani and Alzahra Hospitals affiliated to Isfahan University of Medical Sciences, Isfahan, Iran. The sampling was performed by multi-stage random cluster sampling method and the informed consent form was filled in by the subjects. Then, all the data were collected through interviews using the Lower Urinary Tract Symptom Score (LUTSS) developed in accordance with the definitions presented by the International Continence Society (ICS) and the International Prostate Symptom Score (I-PSS). The data were analyzed using descriptive and inferential statistical tests in SPSS and the significance level was considered to be less than 0.050. Results The prevalence rate of lower urinary tract symptoms (LUTS) was 87.6% among all the subjects, with a similar rate among women (88.0%) and men (86.0%). There was a significant difference between the two groups of men and women in terms of the prevalence of stress urinary incontinence (SUI), intermittent urine flow, hesitancy, straining, and dribbling (P < 0.050). There was no significant difference between the two groups of women and men in terms of the prevalence of other symptoms (P > 0.050). Moreover, there was a significant difference between the degree of LUTS with age, marital status, education, duration of illness, clinical course, and disability (P < 0.05). Conclusions A high prevalence of LUTS was found among patients with MS, with similar rates in men and women, and the nature of the urinary complaints and LUTS was different among men and women with MS. Therefore, it is recommended that the health system take necessary measures regarding timely detection and treatment of LUTS among these patients in order to prevent secondary outcomes and improve the quality of life (QOL) of patients with MS.

Download Full-text

Biofeedback in the treatment of lower urinary tract symptoms in children

Medicinski pregled ◽

10.2298/mpns1806167d: ◽

2018 ◽

Vol 71 (5-6) ◽

pp. 167-170

Author(s):

Marina Djermanov ◽

Dragana Zivkovic

Keyword(s):

Urinary Tract ◽

Overactive Bladder ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Pediatric Population ◽

Dysfunctional Voiding ◽

Positive Effects ◽

Urinary Tract Symptoms ◽

Biofeedback Treatment ◽

Lower Urinary

Introduction. Bladder and bowel dysfunction describes a large spectrum of lower urinary tract symptoms along with fecal elimination issues. The aim of the study was to analyze the effects of biofeedback treatment in children with lower urinary tract symptoms. Material and Methods. A prospective study analyzed the effects of biofeedback treatment conducted in children with lower urinary tract symptoms. Questionnaires and voiding diaries were collected prior to the treatment. The patients were followed for two weeks on daily basis. After the completion of the treatment, the data from voiding diaries and questionnaires were analyzed. Results. A total of 18 children were referred for biofeedback treatment. Seven patients had an overactive bladder. seven had isolated dysfunctional voiding, and in the third group three had difficulties starting to void and one had daily incontinence with dysfunctional voiding. A total of 14 patients presented with improvement of symptoms. The analyzed data showed no measurable improvement in one patient, even though he reported a personal feeling of improvement. Three patients without positive effects of the therapy were immature and non-cooperative. In six out of seven patients with overactive bladder with urine leakage, the symptom disappeared by the end of the treatment. Conclusion. Biofeedback is a very useful tool in the treatment of lower urinary tract symptoms in pediatric population. Although the main indication for initiating this therapy is dysfunctional voiding, the study showed an improvement of symptoms in patients with overactive bladder as well.

Download Full-text